临床药物治疗杂志
臨床藥物治療雜誌
림상약물치료잡지
CLINICAL MEDICATION JOURNAL
2015年
4期
37-40
,共4页
晚期胃癌%扶正清解方%胃癌根治术%免疫功能%毒副作用
晚期胃癌%扶正清解方%胃癌根治術%免疫功能%毒副作用
만기위암%부정청해방%위암근치술%면역공능%독부작용
cadvanced gastric cancer%FuZhengQingJie%gastrectomy%immune function%toxicity
目的:探讨药物辅助胃癌根治术用于晚期胃癌治疗中对患者生活质量的影响.方法:晚期胃癌患者98例根据随机数字表法分为治疗组与对照组各49例,两组都给予D2根治性切除术结合XELOX辅助化疗,在此基础上治疗组加用扶正清解方进行治疗.结果:治疗组的Karnofsky评分改善情况明显优于对照组(P<0.05).治疗组的骨髓抑制、肝功能损伤与肾功能损伤等毒副反应程度与比例明显少于对照组(P<0.05).治疗后两组的CD3+和CD4+值都明显提高(P<0.05),同时治疗组的CD3+和CD4+值明显高于对照组(P<0.05).随访到2015年4月,治疗组与对照组的平均生存期为(22.44±2.14)月与(16.98±2.41)月,差异具有流计学意义(P<0.05).结论:扶正清解方辅助胃癌根治术用于晚期胃癌能有效改善患者的免疫功能,减少化疗毒副作用,从而提高总体治疗效果,延长患者的生存期.
目的:探討藥物輔助胃癌根治術用于晚期胃癌治療中對患者生活質量的影響.方法:晚期胃癌患者98例根據隨機數字錶法分為治療組與對照組各49例,兩組都給予D2根治性切除術結閤XELOX輔助化療,在此基礎上治療組加用扶正清解方進行治療.結果:治療組的Karnofsky評分改善情況明顯優于對照組(P<0.05).治療組的骨髓抑製、肝功能損傷與腎功能損傷等毒副反應程度與比例明顯少于對照組(P<0.05).治療後兩組的CD3+和CD4+值都明顯提高(P<0.05),同時治療組的CD3+和CD4+值明顯高于對照組(P<0.05).隨訪到2015年4月,治療組與對照組的平均生存期為(22.44±2.14)月與(16.98±2.41)月,差異具有流計學意義(P<0.05).結論:扶正清解方輔助胃癌根治術用于晚期胃癌能有效改善患者的免疫功能,減少化療毒副作用,從而提高總體治療效果,延長患者的生存期.
목적:탐토약물보조위암근치술용우만기위암치료중대환자생활질량적영향.방법:만기위암환자98례근거수궤수자표법분위치료조여대조조각49례,량조도급여D2근치성절제술결합XELOX보조화료,재차기출상치료조가용부정청해방진행치료.결과:치료조적Karnofsky평분개선정황명현우우대조조(P<0.05).치료조적골수억제、간공능손상여신공능손상등독부반응정도여비례명현소우대조조(P<0.05).치료후량조적CD3+화CD4+치도명현제고(P<0.05),동시치료조적CD3+화CD4+치명현고우대조조(P<0.05).수방도2015년4월,치료조여대조조적평균생존기위(22.44±2.14)월여(16.98±2.41)월,차이구유류계학의의(P<0.05).결론:부정청해방보조위암근치술용우만기위암능유효개선환자적면역공능,감소화료독부작용,종이제고총체치료효과,연장환자적생존기.
Objective:To investigate the effect of pharmacotherapy combined radical gastrectomy on quality of life for advanced gastric cancer.Methods: 98 patients with advanced gastric cancer were randomly divided into the treatment group and the control group, and both groups were given D2 radical resection combined with XELOX chemotherapy, and the treatment group was given the FuZhengQingJie additionally for treatment.Results: The Karnofsky score improvement in the treatment group was better than that in the control group (P<0.05). The degree of bone marrow suppression, liver dysfunction and renal injury in the treatment group was signiifcantly lower than those in the control group(P<0.05). The CD3+ and CD4+ values after treatment in both groups were signiifcantly increased (P<0.05), while CD3+ and CD4+ values in the treatment group were significantly higher in the treatment group (P<0.05). Followed-up to April 2015, the average survival of treatment group and the control group were (22.44 ± 2.14) months and (16.98 ± 2.41) months respectively, and the average survival of treatment group was significantly longer than the control group (P<0.05).Conclusion: The FuZhengQingJie medicine combined radical gastrectomy for advanced gastric cancer can improve immune function and reduce the side effects of chemotherapy, thereby increasing the overall treatment effect and prolong survival of patients.
